“In order to serve more patients that need cell therapy today, Kite is rapidly growing both through global expansion and seeking new indications for our existing approved CAR T-cell therapies. Kite’s new manufacturing facility in Frederick, MD for commercial production of CAR T-cell therapy is not part of the purchase agreement. Under the terms of the agreement, Kite will receive a one-time upfront payment from BioNTech to purchase Kite’s individualized solid tumor neoantigen TCR discovery platform as well as the Gaithersburg R&D and clinical manufacturing facility. To support its growing cell therapy pipeline, BioNTech plans to further invest in the site including hiring additional personnel. “It also strengthens our presence in the U.S., building on our successful integration of adoptive T-cell and neoantigen TCR therapies as part of our acquisition of Neon Therapeutics last year.”Īll Kite employees at the Gaithersburg facility will be offered employment with BioNTech prior to the date of closing. and advance at the forefront of individualized cell therapies,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. The acquisition of the Kite facility and its individualized TCR platform allows us to accelerate the clinical development of our cell therapies in the U.S. “The development of individualized cancer therapies is at the core of our work at BioNTech. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. MAINZ, Germany & SANTA MONICA, Calif.-(BUSINESS WIRE)-īioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. Transaction Expected to Close By End of July 2021. Kite Remains Focused on Rapid Advancement of Current CAR T-Cell Therapies to Reach More Patients and Further Optimize Therapeutic Potential of Cell Therapy. Deal Strengthens BioNTech’s Cell Therapy Pipeline By Accelerating Individualized Solid Tumor Neoantigen TCR Cell Therapy Research and Development Program and Adding Manufacturing Footprint in North America.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |